| Product Code: ETC10416559 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Relapsing Remitting Multiple Sclerosis Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Relapsing Remitting Multiple Sclerosis Market - Industry Life Cycle |
3.4 Israel Relapsing Remitting Multiple Sclerosis Market - Porter's Five Forces |
3.5 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume Share, By Mechanism of Action, 2021 & 2031F |
3.7 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Israel Relapsing Remitting Multiple Sclerosis Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of relapsing-remitting multiple sclerosis in Israel |
4.2.2 Rising awareness and diagnosis rates of multiple sclerosis in the country |
4.2.3 Advancements in treatment options and therapies for relapsing-remitting multiple sclerosis |
4.3 Market Restraints |
4.3.1 High treatment costs associated with managing relapsing-remitting multiple sclerosis |
4.3.2 Limited access to specialized healthcare services for multiple sclerosis patients in certain regions of Israel |
5 Israel Relapsing Remitting Multiple Sclerosis Market Trends |
6 Israel Relapsing Remitting Multiple Sclerosis Market, By Types |
6.1 Israel Relapsing Remitting Multiple Sclerosis Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Drug Type, 2021 - 2031F |
6.1.3 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Immunomodulators, 2021 - 2031F |
6.1.4 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Monoclonal Antibodies, 2021 - 2031F |
6.1.5 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Interferons, 2021 - 2031F |
6.1.6 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By S1P Receptor Modulators, 2021 - 2031F |
6.2 Israel Relapsing Remitting Multiple Sclerosis Market, By Mechanism of Action |
6.2.1 Overview and Analysis |
6.2.2 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By T-Cell Suppression, 2021 - 2031F |
6.2.3 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By B-Cell Targeting, 2021 - 2031F |
6.2.4 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Cytokine Regulation, 2021 - 2031F |
6.2.5 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Immune Cell Migration, 2021 - 2031F |
6.3 Israel Relapsing Remitting Multiple Sclerosis Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Oral, Injectable, 2021 - 2031F |
6.3.3 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By IV Infusion, 2021 - 2031F |
6.3.4 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Subcutaneous, Intramuscular, 2021 - 2031F |
6.3.5 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Oral, 2021 - 2031F |
6.4 Israel Relapsing Remitting Multiple Sclerosis Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Hospitals, Clinics, 2021 - 2031F |
6.4.3 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Specialty Centers, 2021 - 2031F |
6.4.4 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Homecare, Clinics, 2021 - 2031F |
6.4.5 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Neurology Centers, 2021 - 2031F |
6.5.2 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Distribution Channel, 2021 - 2031F |
6.5.3 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Retail Pharmacies, Online Pharmacies, 2021 - 2031F |
6.5.4 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Specialty Pharmacies, Hospital Pharmacies, 2021 - 2031F |
6.5.5 Israel Relapsing Remitting Multiple Sclerosis Market Revenues & Volume, By Online Drug Stores, 2021 - 2031F |
7 Israel Relapsing Remitting Multiple Sclerosis Market Import-Export Trade Statistics |
7.1 Israel Relapsing Remitting Multiple Sclerosis Market Export to Major Countries |
7.2 Israel Relapsing Remitting Multiple Sclerosis Market Imports from Major Countries |
8 Israel Relapsing Remitting Multiple Sclerosis Market Key Performance Indicators |
8.1 Average time from symptom onset to diagnosis for relapsing-remitting multiple sclerosis patients in Israel |
8.2 Percentage of relapsing-remitting multiple sclerosis patients in Israel receiving disease-modifying therapies |
8.3 Number of clinical trials and research studies focused on relapsing-remitting multiple sclerosis in Israel |
9 Israel Relapsing Remitting Multiple Sclerosis Market - Opportunity Assessment |
9.1 Israel Relapsing Remitting Multiple Sclerosis Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 Israel Relapsing Remitting Multiple Sclerosis Market Opportunity Assessment, By Mechanism of Action, 2021 & 2031F |
9.3 Israel Relapsing Remitting Multiple Sclerosis Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Israel Relapsing Remitting Multiple Sclerosis Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Israel Relapsing Remitting Multiple Sclerosis Market - Competitive Landscape |
10.1 Israel Relapsing Remitting Multiple Sclerosis Market Revenue Share, By Companies, 2024 |
10.2 Israel Relapsing Remitting Multiple Sclerosis Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here